Q2
BOLD — Q2 2026 Financial Report Analysis
Boundless Bio dropped its last drug candidate after poor absorption in early human dosing and agreed to merge with gene-editing firm Serapha Bio; Q2 net loss widened to $23.7M on wind-down charges, and holders expect a $44–48M cash dividend plus 3.69% of the combined company.